A Third Rock-backed player charts a new course against transcription factors. Do 'switch sites' hold the magic sauce?
Long known for their role in guiding gene expression but considered “undruggable,” DNA binding transcription factors have long been a Holy Grail for drug developers. Now, a new startup from Third Rock Ventures thinks it could have the juice to get after transcription factors once and for all — and it all started with a “flare” of inspiration from an article out of an Oxford lab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.